Researchers found that a new cell therapy called CardiAMP could help treat ischemic heart failure, a serious condition affecting the heart’s ability to pump blood. This therapy uses a patient’s own bone marrow cells to improve heart function and has shown promising results in clinical trials. With the backing of Japan’s Pharmaceutical and Medical Device Agency (PMDA), BioCardia, the company behind CardiAMP, is moving closer to regulatory approval, which could make this treatment available to many patients struggling with heart failure.

This matters because ischemic heart failure affects a significant number of people, with around 20,000 patients in Japan potentially eligible for this therapy. If approved, CardiAMP could improve heart health by increasing blood flow and reducing damage to heart tissue. For those living with heart failure, this could mean better energy levels, improved quality of life, and a greater ability to engage in everyday activities.

The current evidence comes from three completed clinical trials, which have shown credible positive outcomes. However, while the PMDA’s support is a good sign, the therapy is still in the regulatory approval phase and not yet available to the public. The timeline for submission is about seven months, and further studies will be required to ensure its safety and effectiveness once it reaches the market.

For now, if you or someone you know is dealing with heart issues, it’s essential to stay informed about new treatments like CardiAMP. Discussing options with a healthcare provider can help you understand the best approaches to managing heart health and staying active as you age.

Source: globenewswire.com